Literature DB >> 9971843

Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection.

X Wang1, J M Bergelson.   

Abstract

Coxsackievirus and adenovirus receptor (CAR) from which the cytoplasmic domain had been deleted and glycosylphosphatidylinositol (GPI)-anchored CAR lacking both transmembrane and cytoplasmic domains were both capable of facilitating adenovirus 5-mediated gene delivery and infection by coxsackievirus B3. These results indicate that the CAR extracellular domain is sufficient to permit virus attachment and entry and that the presence of a GPI anchor does not prevent infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971843      PMCID: PMC104505     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Internalization of a major group human rhinovirus does not require cytoplasmic or transmembrane domains of ICAM-1.

Authors:  D E Staunton; A Gaur; P Y Chan; T A Springer
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

2.  Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells.

Authors:  F G Giancotti; E Ruoslahti
Journal:  Cell       Date:  1990-03-09       Impact factor: 41.582

3.  Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction.

Authors:  R M Horton; Z L Cai; S N Ho; L R Pease
Journal:  Biotechniques       Date:  1990-05       Impact factor: 1.993

4.  Human immunodeficiency virus infection is efficiently mediated by a glycolipid-anchored form of CD4.

Authors:  D C Diamond; R Finberg; S Chaudhuri; B P Sleckman; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

5.  Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface.

Authors:  D A Brown; J K Rose
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

6.  Internalization of glycosyl-phosphatidylinositol (GPI)-anchored lymphocyte proteins. II. GPI-anchored and transmembrane molecules internalize through distinct pathways.

Authors:  A Bamezai; V S Goldmacher; K L Rock
Journal:  Eur J Immunol       Date:  1992-01       Impact factor: 5.532

7.  Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.

Authors:  M E Medof; E I Walter; W L Roberts; R Haas; T L Rosenberry
Journal:  Biochemistry       Date:  1986-11-04       Impact factor: 3.162

8.  Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.

Authors:  M A Davitz; M G Low; V Nussenzweig
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

9.  Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.

Authors:  D M Lublin; K E Coyne
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

10.  Endocytosis of glycophospholipid-anchored and transmembrane forms of CD4 by different endocytic pathways.

Authors:  G A Keller; M W Siegel; I W Caras
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  52 in total

1.  Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.

Authors:  D A Einfeld; D E Brough; P W Roelvink; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer.

Authors:  R J Pickles; J A Fahrner; J M Petrella; R C Boucher; J M Bergelson
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.

Authors:  C J Cohen; J T Shieh; R J Pickles; T Okegawa; J T Hsieh; J M Bergelson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Adenovirus serotype 30 fiber does not mediate transduction via the coxsackie-adenovirus receptor.

Authors:  Lane K Law; Beverly L Davidson
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  The interaction between the fiber knob domain and the cellular attachment receptor determines the intracellular trafficking route of adenoviruses.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Vladimir Ternovoi; Anuj Gaggar; Helen Gharwan; André Lieber
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Transgenic expression of the coxsackie/adenovirus receptor enables adenoviral-mediated gene delivery in naive T cells.

Authors:  Y Y Wan; R P Leon; R Marks; C M Cham; J Schaack; T F Gajewski; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

7.  Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells.

Authors:  Theresa Vincent; Ralf F Pettersson; Ronald G Crystal; Philip L Leopold
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  A mouse model for adenovirus gene delivery.

Authors:  T Tallone; S Malin; A Samuelsson; J Wilbertz; M Miyahara; K Okamoto; L Poellinger; L Philipson; S Pettersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

9.  Analysis of the expression of coxsackievirus and adenovirus receptor in five colon cancer cell lines.

Authors:  Yassan Abdolazimi; Majid Mojarrad; Mehrdad Pedram; Mohammad Hossein Modarressi
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

10.  Bronchoalveolar fluid is not a major hindrance to virus-mediated gene therapy in cystic fibrosis.

Authors:  C P Rooney; G M Denning; B P Davis; D M Flaherty; J A Chiorini; J Zabner
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.